Human Immunodeficiency Virus Clinical Trials

24 recruiting

Human Immunodeficiency Virus Trials at a Glance

49 actively recruiting trials for human immunodeficiency virus are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Not Applicable with 18 trials, with the heaviest enrollment activity in Cape Town, Durban, and Los Angeles. Lead sponsors running human immunodeficiency virus studies include Merck Sharp & Dohme LLC, University of California, San Francisco, and Johns Hopkins University.

Browse human immunodeficiency virus trials by phase

Treatments under study

About Human Immunodeficiency Virus Clinical Trials

Looking for clinical trials for Human Immunodeficiency Virus? There are currently 24 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Human Immunodeficiency Virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Human Immunodeficiency Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled47 locationsNCT07266831
Recruiting

Harm Reduction in HIV Primary Care for PLWH Who Use Drugs

Substance UseHuman Immunodeficiency VirusStigma, Social
University of Pittsburgh768 enrolled3 locationsNCT05404750
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Not Applicable

Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care

HIV (Human Immunodeficiency Virus)StigmaContinuum of Care
University of California, Los Angeles80 enrolled1 locationNCT07495059
Recruiting
Phase 4

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

Smoking CessationHuman Immunodeficiency Virus (HIV)
New York University500 enrolled1 locationNCT06598397
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled78 locationsNCT07044297
Recruiting
Phase 1

HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong

Human Immunodeficiency VirusHuman Immunodeficiency Virus I Infection
Immuno Cure Holding (HK) Limited22 enrolled1 locationNCT07530198
Recruiting
Phase 4

Low Dose Naltrexone for Pain in Patients With HIV

Human Immunodeficiency VirusChronic Neuropathic Pain
Emory University60 enrolled3 locationsNCT05537935
Recruiting
Not Applicable

Persuasive Health Communication Intervention for HIV/HCV

Human Immunodeficiency Virus (HIV)Hepatitis C (HCV)
University of South Florida2,000 enrolled1 locationNCT05968573
Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled29 locationsNCT07071623
Recruiting
Not Applicable

ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

Contact With or Exposure to Human Immunodeficiency Virus
Oswaldo Cruz Foundation1,500 enrolled8 locationsNCT07497594
Recruiting
Not Applicable

The Trans-Led Care Study

Substance AbuseSubstance AddictionSubstance Use Disorder (SUD)+2 more
Illinois Institute of Technology124 enrolled1 locationNCT06880705
Recruiting
Phase 2

Baricitinib for Reduction of HIV - CNS

Human Immunodeficiency Virus
William Tyor95 enrolled2 locationsNCT05452564
Recruiting

Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment

HIV (Human Immunodeficiency Virus)
University Hospital, Toulouse30 enrolled1 locationNCT07062614
Recruiting
Not Applicable

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

HIV (Human Immunodeficiency Virus)
University of California, San Francisco33 enrolled1 locationNCT07115901
Recruiting
Not Applicable

Improving Access to HIV Testing for Children in Uganda

HIV (Human Immunodeficiency Virus)
University of California, San Francisco400 enrolled1 locationNCT07236905
Recruiting
Not Applicable

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical CancerHuman Papillomavirus (HPV) InfectionHuman Immunodeficiency Virus (HIV) Infection
University of California, Irvine420 enrolled1 locationNCT07209917
Recruiting

Voluntary HIV Screening in the General Population in France

Human Immunodeficiency Virus (HIV)
Université de Reims Champagne-Ardenne1,000 enrolled1 locationNCT07418385
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830